On transparency in regulatory decision making for approval of biosimilars

Published on: 15 November 2016

A must hear! If you are interested in biosimilar products and the pharma take on how these are approved today, take some minutes to listen to Thomas Shreitmuller’s take. Thomas Schreitmueller is the Global Lead for Regulatory Policy for Biologics – F. Hoffmann-La Roche. In this capacity he represents his company in various WHO, ICH, IFPMA, EFPIA, EBE, and BIO-biotech working groups. He is also a member of the Organizing Committee of the CMC Strategy Forum Europe. He also gives here Fifarma’s position on “transparency” in regulatory decision making on the approval for biosimilar products.